The Safety and Effectiveness of AA4500 in Subjects With Peyronie's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

147

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions
Peyronie's Disease
Interventions
BIOLOGICAL

AA4500

2 single injections of study drug per each treatment series up to three treatment series total in study. Each treatment series was separated by 6 weeks.

BIOLOGICAL

Placebo

2 single injections of study drug per each treatment series up to three treatment series total in study. Each treatment series is separated by 6 weeks.

Trial Locations (12)

10016

University Urology Associates, New York

11219

Maimonides Medical Center Divison of Urology, Brooklyn

23502

Urology of Virginia (a division of Sentara Medical Group), Norfolk

33180

South Florida Medical Research, Aventura

45212

Tristate Urologic Services, Cincinnati

46825

Northeast Indiana Research, LLC, Fort Wayne

47130

Metropolitan Urology, PSC, Jeffersonville

60612

Urology Specialists, SC, Chicago

77030

Baylor College of Medicine, Scott Department of Urology, Houston

91505

Urology Associates Medical Group, Burbank

06762

Urology Specialists Connecticut Clinical Research Center, LLC, Middlebury

06511

The Urology Center, PC, New Haven

Sponsors
All Listed Sponsors
lead

Endo Pharmaceuticals

INDUSTRY